Ovid Therapeutics Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ovid Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View analyst ratings for Ovid Therapeutics or view top-rated stocks.

Wall Street analysts have given Ovid Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ovid Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Ovid Therapeutics.

Ovid Therapeutics Inc. (NASDAQ:OVID) issued its earnings results on Monday, August, 16th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.07.
View Ovid Therapeutics' earnings history.

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OVID stock has increased by 25.7% and is now trading at $3.37.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 12 month target prices for Ovid Therapeutics' stock. Their forecasts range from $4.00 to $40.00. On average, they expect Ovid Therapeutics' stock price to reach $10.83 in the next twelve months. This suggests a possible upside of 221.5% from the stock's current price.
View analysts' price targets for Ovid Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ovid Therapeutics include POINT Biopharma Global (PNT), Design Therapeutics (DSGN), BeyondSpring (BYSI), Praxis Precision Medicines (PRAX), Amphastar Pharmaceuticals (AMPH), Crinetics Pharmaceuticals (CRNX), Phibro Animal Health (PAHC), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), BioXcel Therapeutics (BTAI), Edgewise Therapeutics (EWTX), Annexon (ANNX), Zogenix (ZGNX), VBI Vaccines (VBIV) and Kiniksa Pharmaceuticals (KNSA).
View all of OVID's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ovid Therapeutics investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Enphase Energy (ENPH), Gilead Sciences (GILD) and Novavax (NVAX).

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Ovid Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.78%), Vanguard Group Inc. (5.17%), BlackRock Inc. (1.77%), Globeflex Capital L P (1.49%), Millennium Management LLC (1.13%) and Wells Fargo & Company MN (0.67%). Company insiders that own Ovid Therapeutics stock include Amit Rakhit, Jeremy M Levin and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends for Ovid Therapeutics.

OVID stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Goldman Sachs Group Inc., Northern Trust Corp, Geode Capital Management LLC, Susquehanna International Group LLP, Charles Schwab Investment Management Inc., and Citadel Advisors LLC.
View insider buying and selling activity for Ovid Therapeutics or view top insider-selling stocks.

OVID stock was purchased by a variety of institutional investors in the last quarter, including Globeflex Capital L P, Millennium Management LLC, BVF Inc. IL, Ergoteles LLC, AQR Capital Management LLC, Morgan Stanley, Morgan Stanley, and Sei Investments Co.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Jeremy M Levin, and Pharmaceutical Co Ltd Takeda.
View insider buying and selling activity for Ovid Therapeutics or or view top insider-buying stocks.

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OVID stock can currently be purchased for approximately $3.37.

Ovid Therapeutics has a market capitalization of $228.93 million and generates $12.62 million in revenue each year. The company earns $-81,040,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis.

Ovid Therapeutics employs 67 workers across the globe.

The official website for Ovid Therapeutics is www.ovidrx.com.

Ovid Therapeutics is headquartered at 1460 Broadway Suite 15044, New York NY, 10036.

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at (646) 661-7661 or via email at [email protected]